Resource data sheet
DNA Bank Top
Please review the QC test results indicated by check icon below as well as clone information before placing your order.

CSU6EG_sh2-hSTAT5AB (#RDB17322)

Short hairpin RNA (shRNA) lentivirus expression vector of human STAT5.

Clone info. Short hairpin RNA (shRNA) lentivirus expression vector of human signal transducer and activator of transcription 5 (STAT5) shRNA, U6 promoter, GFP. The target sequences for both STAT5A and STAT5B is 5'-GCAGAAACTGTTCAACAACAG-3' with a harpin 5'-CTCGAG-3'.
Comment Expression was confirmed by the deposotor with the observation of GFP expression.
Vector backbone CSU6EG (plasmid)
Size of vector backbone 10 kb
Selectable markers Amp^r.
Growth conditions LB+Ampicilin, 37℃
Gene/insert name human STAT5A cDNA human STAT5B cDNA
Depositor|Developer Yoshitomi, Hiroyuki |
 

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
Ordering forms
Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ]
MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ]
Please visit Ordering instruction.[link] 
Terms and conditions for distribution In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature designated by the DEPOSITOR is requested (Kobayashi S. et al. Eur. J. Immunol. 46(2), 360-371, 2016). The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit organization for a not-for-profit research. For use of the BIOLOGICAL RESOURCE by a for-profit organization, the RECIPIENT must reach agreement on terms and conditions of use of it with DEPOSITOR and must obtain a prior written consent from the DEPOSITOR.
Additional terms and conditions:
The RECIPIENT agrees to expressly describe the late Dr. Hiroyuki Miyoshi as the Developer of the lentivirus vector.

Further transfer, provision of services or resale of the Zeocin resistance gene, and the Deposited Materials is prohibited without InvivoGen's prior written consent. In addition, InvivoGen's Limited Use Label License applies to your use of this product.
Remarks
Zeocin® is a trademark of InvivoGen registered with the United States Patent and Trademark Office and foreign equivalents. See InvivoGen Limited Use Label License.
提供案内 (日本国内) [open/close]

必要書類
提供依頼書  [依頼書の記入例 ]
提供同意書 (MTA, 非営利学術目的用)[Word] [MTAの記入例 ]
手続きの概要は、「レンチウイルスベクターの提供申し込み」をご覧ください。
MTAに書く使用条件 利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する(Kobayashi S. et al. Eur. J. Immunol. 46(2), 360-371, 2016)。学術機関の学術研究に限る。営利機関の利用希望者は、事前に利用条件等につき寄託者と合意し、提供承諾を得ること。
付加的使用条件：
レンチウイルスベクターについて、本件研究材料を利用した研究結果等を発表する際は、レンチウイルスベクターが故三好浩之博士により開発されたことを明示する。

InvivoGen社の事前の書面による同意がない限り、ゼオシン耐性遺伝子および寄託マテリアルの第三者への移転、サービスの提供、または再販売は禁止されています。また、ご利用に際してInvivoGen社のLimited Use Label Licenseが適用されます。
備考
ZeocinはInvivoGen社の製品です。Zeocin®は、米国特許商標庁および米国外の同等機関に登録されたInvivoGen社の商標です。InvivoGen Limited Use Label Licenseをご確認ください。

Catalog # Resource name Availability Shipping form Fee
RDB17322 CSU6EG_sh2-hSTAT5AB Under QC test. Please contact us. DNA solution

check Please wait for results of QC test to be uploaded. This clone will be sequenced a portion for examination.
Ordering instruction of plasmids [in Japanese] [in English]

How to cite this biological resource

Materials & Methods section:

The CSU6EG_sh2-hSTAT5AB was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB17322).

Reference section:

Kobayashi, S., Watanabe, T., Suzuki, R., Furu, M., Ito, H., Ito, J., Matsuda, S., Yoshitomi, H., TGF-beta induces the differentiation of human CXCL13-producing CD4(+) T cells. Eur. J. Immunol. 46 (2): 360-371 (2016). PMID 26541894. [PubMed] [Article] [RRC of NBRP]

Further references such as user reports and related articles (go to bottom)

QC test results

check Please wait for results of QC test to be uploaded. This clone will be sequenced a portion for examination.

References

Original, user report and related articles

original Kobayashi, S., TGF-beta induces the differentiation of human CXCL13-producing CD4(+) T cells. Eur. J. Immunol. 46 (2): 360-371 (2016). PMID 26541894. [PubMed] [Article] [RRC of NBRP]